| Politician | Action | Description | Traded |
|---|---|---|---|
| Buy | PORTIVE CORPORATION CMN | Feb 9, 2025 | |
| Buy | Pacira BioSciences, Inc. | May 6, 2021 | |
| Buy | Pacira BioSciences, Inc. | Apr 20, 2021 | |
| Buy | Pacira BioSciences, Inc. | Jan 15, 2021 | |
| Buy | Pacira BioSciences, Inc. | Nov 2, 2020 | |
| Buy | Pacira BioSciences, Inc. | Aug 23, 2020 | |
| Sell | PERRIGO COMPANY CMN | Aug 12, 2019 | |
| Buy | PACIRA PHARMACEUTICALS INCOR | Jan 13, 2017 | |
| Sell | PACIRA PHARMACEUTICALS INCOR | Dec 13, 2016 | |
| Buy | PACIRA PHARMACEUTICALS INCOR | Jan 1, 2016 |
This page tracks congressional stock trading activity in Pacira BioSciences, Inc. (PCRX) in the Healthcare sector. Disclosed Capitol has indexed 13 disclosed congressional trades involving PCRX. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.
As of March 2025 — Disclosed Capitol has tracked 13 disclosed congressional trades in Pacira BioSciences, Inc. (PCRX) — 4:4 buy-heavy ratio — led by Jim Renacci (R).
| Date | Politician | Party | Action | Amount |
|---|---|---|---|---|
| Feb 9, 2025 | Ro Khanna | D | Purchase | $1,001 - $15,000 |
| May 6, 2021 | Tom Malinowski | D | Buy | $1,001 - $15,000 |
| Apr 20, 2021 | Tom Malinowski | D | Buy | $1,001 - $15,000 |
| Jan 15, 2021 | Tom Malinowski | D | Buy | $1,001 - $15,000 |
| Nov 2, 2020 | Tom Malinowski | D | Buy | $1,001 - $15,000 |
| Aug 23, 2020 | Tom Malinowski | D | Buy | $1,001 - $15,000 |
| Aug 12, 2019 | Ro Khanna | D | Sale | $1,001 - $15,000 |
| Jan 13, 2017 | Jim Renacci | R | Purchase | $1,001 - $15,000 |
| Dec 13, 2016 | Jim Renacci | R | Sale | $1,001 - $15,000 |
| Jan 1, 2016 | Jim Renacci | R | Purchase | $50,001 - $100,000 |
Across the 13 disclosed congressional trades in Pacira BioSciences, Inc. (PCRX), members of Congress have reported 4 buys and 4 sells. The average 30-day alpha vs. the S&P 500 is 0.14%.
For fiscal year 2025, Pacira BioSciences, Inc. reported revenue of $726.4M and net income of $7.0M, per SEC filings.
Most recent reported quarter: Q2 FY2026 — revenue $192.4M, net income $4.7M.
Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.